<DOC>
	<DOCNO>NCT00000914</DOCNO>
	<brief_summary>The purpose study compare different treatment HIV infection see work best low HIV level raise number CD4 cell ( cell immune system fight infection ) , HIV-positive individual protease inhibitor-containing drug regimen least 16 week . Researchers find combination anti-HIV therapy ( multiple drug give together ) help prevent AIDS-related illness help people AIDS live longer . In study , anti-HIV drug efavirenz ( EFV ) test 1 2 protease inhibitor ( PIs ) see combination work best treat HIV infection . EFV show limit amount HIV virus produce infected cell .</brief_summary>
	<brief_title>A Study Effectiveness Different Anti-HIV Treatments HIV-Positive Individuals Who Have Been Protease Inhibitor-Containing Drug Regimen Least 16 Weeks</brief_title>
	<detailed_description>Current recommendation initial treatment HIV infection center reduction plasma HIV level . It show combination 2 nucleoside reverse transcriptase inhibitor ( NRTIs ) PI effective barrier disease progression . This study attempt demonstrate data . Two option available patient whose initial PI-containing regimen fail suppress viral replication . Option 1 consist immediate versus defer use nonnucleoside reverse transcriptase inhibitor ( NNRTI ) . Patients choose Option 1 randomize 1 2 group : 1 . Ritonavir ( RTV ) plus soft gelatin capsule saquinavir ( SQV-SGC ) plus efavirenz ( EFV ) . 2 . RTV plus SQV-SGC . Option 2 consist treatment single PI versus double PI . Patients choose Option 2 randomize 1 2 group : 1 . Nelfinavir ( NFV ) plus EFV . 2 . RTV plus SQV-SGC plus EFV . Patients fail NFV Option 2 randomize one two group : 1 . Indinavir ( IDV ) plus EFV . 2 . RTV plus SQV-SGC plus EFV . Patients remain study treatment regimens 8 week . Follow-up visit , include history physical evaluation , take place specify interval next 12 month .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Nelfinavir</mesh_term>
	<mesh_term>HIV Protease Inhibitors</mesh_term>
	<mesh_term>Indinavir</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<mesh_term>Protease Inhibitors</mesh_term>
	<criteria>Inclusion Criteria You may eligible study : Are HIVpositive . Have HIV RNA count least 400 copies/ml . Are least 13 year old ( need consent 18 ) . Have antiretroviral treatment ( include least 2 NRTIs ) least 16 week prior study entry . Agree practice abstinence use effective method birth control , include barrier method , study . Exclusion Criteria You eligible study : Are pregnant breastfeeding . Have active opportunistic ( HIVassociated ) infection . Have take nelfinavir ( NFV ) 2 week fail indinavir/ritonavir ( IDV/RTV ) treatment take IDV/RTV 2 week fail NFV treatment . Have use protease inhibitor NFV IDV/RTV 2 week . Have use nonnucleoside reverse transcriptase inhibitor ( NNRTI ) 1 week .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>HIV Protease Inhibitors</keyword>
	<keyword>Ritonavir</keyword>
	<keyword>Indinavir</keyword>
	<keyword>Saquinavir</keyword>
	<keyword>Reverse Transcriptase Inhibitors</keyword>
	<keyword>Viral Load</keyword>
	<keyword>Nelfinavir</keyword>
</DOC>